

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Cetuximab for the treatment of advanced non-small cell lung cancer

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Merck-Serono (cetuximab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Age Concern England • Breathe Easy • British Lung Foundation • Cancer Black Care • Cancer Equality • Cancer Voices • Cancerbackup • Counsel and Care • Help the Aged • Macmillan Cancer Relief • Marie Curie Cancer Care • National Cancer Alliance • National Council for Palliative Care • Roy Castle Lung Cancer Foundation • Specialised Healthcare Alliance • Sue Ryder Care • Tenovus Cancer Information Centre ▪ UK Lung Cancer Coalition <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Respiratory Nurse Specialists • British Association for Services to the Elderly • British Oncological Association (BOA) • British Psychosocial Oncology Society • British Thoracic Society • Cancer Networks Pharmacists Forum • Cancer Research UK 	<p><u>General</u></p> <ul style="list-style-type: none"> • Age Concern Cymru • Board of Community Health Councils in Wales • British National Formulary • Cancer Care Cymru • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency (MHRA) • National Public Health Service for Wales • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Bristol-Myers Squibb Pharmaceuticals Ltd (carboplatin, paclitaxel) • Eli Lilly & Co Ltd (gemcitabine) • Mayne Pharma plc (cisplatin, paclitaxel, vinorelbine) • Medac (UK) (vinorelbine) • Pfizer Ltd (cisplatin) • Pierre Fabre (vinorelbine) • Sanofi-Aventis Ltd (docetaxel) • Teva UK Ltd (carboplatin, cisplatin, paclitaxel) • Wockhardt UK (carboplatin, cisplatin, paclitaxel) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Institute of Cancer Research • MRC CTU - Lung Cancer and

Appendix C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • General Practice Airways Group • National Association of Primary Care • National Lung Cancer Forum for Nurses • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians (Medical Oncology Joint Special Committee) • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society (UKONS) <p><u>Others</u></p> <ul style="list-style-type: none"> • Blackburn with Darwen PCT • Blaenau Gwent LHB • Department of Health • Welsh Assembly Government 	<p>Mesothelioma Group</p> <ul style="list-style-type: none"> • National Cancer Research Institute <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Evidence Review Group tbc • National Coordinating Centre for Health Technology Assessment <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • (None)

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

Manufacturer table

The matrix lists the manufacturers who have been invited to participate in a technology appraisal. As an appraisal progresses the matrix may not necessarily list all the relevant products relating to it (as manufacturers may decide that they do not wish to be involved). This table has been produced to capture all the related products for easy identification of interests for anyone involved in the appraisal.

Consultees	
Manufacturer	Generic Name
Merck-Serono	cetuximab
Commentators	
Manufacturer	Generic Name
Bristol-Myers Squibb Pharmaceuticals Ltd	carboplatin, paclitaxel
Eli Lilly & Co Ltd	gemcitabine
Mayne Pharma plc	cisplatin, paclitaxel, vinorelbine
Medac (UK)	vinorelbine
Pfizer Ltd	cisplatin
Pierre Fabre	vinorelbine
Sanofi-Aventis Ltd	docetaxel
Teva UK Ltd	carboplatin, cisplatin, paclitaxel

Appendix C

Wockhardt UK	carboplatin, cisplatin, paclitaxel
--------------	------------------------------------